To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.
Age ≥ 18 years
Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023
Within 48 hours after the first onset
National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points
Pre-stroke modified Rankin Scale (mRS) score ≥ 2
Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage
patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia
Patients undergoing endovascular thrombectomy
Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead sponsor
Nanfang Hospital, Southern Medical University
Collaborator